1. Market Research
  2. > Biotechnology Market Trends
  3. > China Blood Product Industry Report, 2016-2019

China Blood Product Industry Report, 2016-2019

  • March 2016
  • -
  • Research In China
  • -
  • 150 pages

Recombinant blood products have developed for many years in foreign countries, but China’s blood products are still proteins extracted from human blood. Thus, reserves and control of plasma resources are the key to the development of Chinese blood product enterprises. Amid the industrial prosperity and favorable policies, China had more than 190 plasma collection stations with the production-use plasma volume of 4, 700 tons and the total lot release volume jumped by 3.36 million bottles year on year to 55.76 million bottles in 2015.

Given stringent requirements on new domestic plasma stations, Shanghai RAAS, China Biologic Products (Shandong Taibang and Guizhou Taibang), Hualan Biological Engineering, Tiantan Biological (including Chengdu Rongsheng) and Yuanda Shuyang which boast abundant capital, powerful R&D strength and rich plasma station resources have become the top five companies in China blood product industry, contributing 61.9% to China’s production-use plasma volume in 2015.

From the point of view of the product structure, human albumin is still the largest type of blood products in China, but its supply has slowed down with a lower contribution 58.8% to China’s total blood product lot release volume in 2015. In recent years, the rising lot release volume of Chinese human albumin is mainly attributed to ample supply of imported products. In 2011-2015, the lot release volume of human albumin imported by China grew at a CAGR of 23.7%, accounting for as much as 55.6% of the total. China's top four human albumin import enterprises --- Behring, Baxter, Grifols and Octapharma seized 50.7% of the total lot release volume in 2015.

China's second largest type of blood products -- human immunoglobulin (ph4) for intravenous injection saw its lot release volume jump by 31.5% year on year to 9.4 million bottles (2.5g / bottle) and its share increase to 16.9% in 2015. Over the same period, tetanus human immunoglobulin, hepatitis B immune globulin and other immune globulin products and coagulation factor products witnessed growth in lot release volume except human rabies immunoglobulin whose lot release volume declined slightly.

The research and development of human blood coagulation factor VIII, human prothrombin complex and other small products in rigid demand has made the most remarkable progress in recent years. Concerning human blood coagulation factor VIII, Shanghai Xinxing had been approved to launched its human blood coagulation factor VIII, Shenzhen Weiguang had entered the new drug registration stage, Guangdong Shuanglin Bio-Pharmacy had embarked on trial production, Jiangxi Boya Bio-Pharmaceutical had gone into clinical phase III (the industrialization is expected in H2 2016), Wuhan Zhongyuan Ruide had obtained clinical approval and Harbin Pacific Biopharmaceutical had applied for clinical approval by the end of 2015.

In order to possess and effectively use plasma raw materials, enterprises are more willing to cooperate mutually in addition to acquisition. In August 2015, China Biologic Products and Xinjiang Deyuan signed a strategic cooperation agreement, under which the former should purchase at least 120/180/200 tons of plasma from the latter per year in the next three years. In 2015, Hebei Da’an Pharmaceutical and Guangdong Weilun actively planned to cooperate on the allocation of plasma fraction II + III, namely the former (it only produces human albumin now) should allocate partial plasma fraction II + III to Guangdong Weilun for the production of immunoglobulin products.

China Blood Product Industry Report, 2016-2019 focuses on the followings:
Market characteristics, operating environments, status quo, etc. of China blood product industry;
Supply and demand, competition pattern, import and export, development forecast, etc. of China blood product industry;
Supply and demand, competition pattern, etc. of 8 blood product segments, including human albumin, human immunoglobulin (pH4) for intravenous injection, blood coagulation factor and tetanus human immunoglobulin;
Operation, blood product business and prospects of 13 major Chinese blood product companies.

Table Of Contents

China Blood Product Industry Report, 2016-2019
1. Overview of Blood Product Industry
1.1 Definition
1.2 Classification
1.3 Recombinant Blood Products
1.4 Industry Chain
1.5 Features

2. Overview of China Blood Product Industry
2.1 Market Size
2.2 Status Quo
2.3 Supply and Demand
2.3.1 Supply
2.3.2 Demand
2.4 Competition
2.5 Operating Environment
2.5.1 International
2.5.2 Policy
2.5.3 Domestic Biopharmaceutical Market
2.6 Import and Export

3. Blood Product Market Segments in China
3.1 Human Albumin
3.1.1 Supply and Demand
3.1.2 Competition Pattern
3.1.3 Prospects
3.2 Human Immunoglobulin (pH4) for Intravenous Injection
3.2.1 Supply and Demand
3.2.2 Competition Pattern
3.3 Blood Coagulation Factor VIII
3.3.1 Supply and Demand
3.3.2 Competition Pattern
3.3.3 Prospects
3.4 Hepatitis B Immunoglobulin
3.4.1 Supply and Demand
3.4.2 Competition Pattern
3.5 Human Immunoglobulin
3.5.1 Supply and Demand
3.5.2 Competition Pattern
3.6 Human Prothrombin Complex
3.6.1 Supply and Demand
3.6.2 Competition Pattern
3.7 Tetanus Immunoglobulin
3.7.1 Supply and Demand
3.7.2 Competition Pattern
3.8 Human Rabies Immunoglobulin
3.8.1 Supply and Demand
3.8.2 Competition Pattern

4. Major Chinese Manufacturers
4.1 China Biologic Products Inc. (NASDAQ: CBPO)
4.1.1 Profile
4.1.2 Operation
4.1.3 Revenue Structure
4.1.4 Customers and Suppliers
4.1.5 RandD and Investment
4.1.6 Shandong Taibang Biological Products Co., Ltd.
4.1.7 Guizhou Taibang Biological Products Co., Ltd.
4.1.8 Xi'an Huitian Blood Products Co., Ltd.
4.1.9 Outlook and Prospects
4.2 Hualan Biological Engineering Inc. (002007.SZ)
4.2.1 Profile
4.2.2 Operation
4.2.3 Revenue Structure
4.2.4 Gross Margin
4.2.5 Customers and Suppliers
4.2.6 RandD and Investment
4.2.7 Blood Products
4.2.8 Outlook and Prospects
4.3 Shanghai RAAS Blood Products Co., Ltd. (002252.SZ)
4.3.1 Profile
4.3.2 Operation
4.3.3 Revenue Structure
4.3.4 Gross Margin
4.3.5 Customers and Suppliers
4.3.6 RandD and Investment
4.3.7 Outlook and Prospects
4.4 Beijing Tiantan Biological Products Co., Ltd. (TIANTANBIO, 600161.SH)
4.4.1 Profile
4.4.2 Operation
4.4.3 Revenue Structure
4.4.4 Customers and Suppliers
4.4.5 Gross Margin
4.4.6 RandD and Investment
4.4.7 Blood Products (Chengdu Rongsheng Pharmaceutical Co., Ltd.)
4.4.8 Outlook and Prospects
4.5 Zhenxing Biopharmaceutical and Chemical Co., Ltd. (000403.SZ)
4.5.1 Profile
4.5.2 Operation
4.5.3 Revenue Structure
4.5.4 Gross Margin
4.5.5 Customers and Suppliers
4.5.6 RandD and Investment
4.5.7 Blood Products (Guangdong Shuanglin Bio-Pharmacy Co., Ltd.)
4.5.8 Outlook and Prospects
4.6 Jiangxi Boya Bio-Pharmaceutical Co., Ltd. (300294.SZ)
4.6.1 Profile
4.6.2 Operation
4.6.3 Revenue Structure
4.6.4 Gross Margin
4.6.5 Customers and Suppliers
4.6.6 RandD and Investment
4.6.7 Outlook and Prospects
4.7 Sichuan Yuanda Shuyang Pharmaceutical Co., Ltd.
4.7.1 Profile
4.7.2 Blood Products
4.8 Shanghai Institute of Biological Products Co., Ltd.
4.8.1 Profile
4.8.2 Blood Products
4.9 Shanxi Kangbao Biological Product Co., Ltd.
4.9.1 Profile
4.9.2 Blood Products
4.10 Green Cross
4.10.1 Profile
4.10.2 Blood Products
4.11 Humanwell Healthcare Group Co., Ltd. (600079.SH)
4.11.1 Profile
4.11.2 Operation
4.11.3 Blood Products (Wuhan Zhongyuan Ruide Biological Product Co., Ltd.)
4.12 Walvax Biotechnology Co, Ltd. (300142.SZ)
4.12.1 Profile
4.12.2 Operation
4.12.3 Blood Products (Hebei Da'an Pharmaceutical Co., Ltd. and Guangdong Weilun Biological Pharmaceutical Co., Ltd.)
4.13 Shenzhen Weiguang Biological Products Co., Ltd.
4.13.1 Profile
4.13.2 Operation
4.13.3 Revenue Structure
4.13.4 Gross Margin
4.13.5 Customers and Suppliers
4.13.6 RandD and Investment
4.13.7 Outlook and Prospects

5. Summary and Forecast
5.1 Company Analysis
5.2 Growth Prediction

Companies Mentioned
China Biologic Products Inc. (NASDAQ: CBPO)
Shandong Taibang Biological Products Co., Ltd.
Guizhou Taibang Biological Products Co., Ltd.
Xi'an Huitian Blood Products Co., Ltd.
Hualan Biological Engineering Inc. (002007.SZ)
Shanghai RAAS Blood Products Co., Ltd. (002252.SZ)
Beijing Tiantan Biological Products Co., Ltd. (TIANTANBIO, 600161.SH)
Chengdu Rongsheng Pharmaceutical Co., Ltd.
Zhenxing Biopharmaceutical and Chemical Co., Ltd. (000403.SZ)
Jiangxi Boya Bio-Pharmaceutical Co., Ltd. (300294.SZ)
Sichuan Yuanda Shuyang Pharmaceutical Co., Ltd.
Shanghai Institute of Biological Products Co., Ltd.
Shanxi Kangbao Biological Product Co., Ltd.
Green Cross
Humanwell Healthcare Group Co., Ltd. (600079.SH)
Walvax Biotechnology Co, Ltd. (300142.SZ)
Shenzhen Weiguang Biological Products Co., Ltd.

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
Bioreactors Market by Scale Range, Material, Usage, Suppliers, End-User, Region - Global Forecast to 2021

Bioreactors Market by Scale Range, Material, Usage, Suppliers, End-User, Region - Global Forecast to 2021

  • $ 18000
  • Industry report
  • September 2016
  • by MarketsandMarkets

The global bioreactors market is expected to reach to USD 1,417 million by 2021 from USD 955 million in 2015, at a CAGR of 6.8% between 2015 and 2021.The increase in adoption of single-use technologies, ...

2016 Europe Cancer Diagnostics Market: Supplier Shares, Country Volume and Sales Segment Forecasts, Innovative Technologies, Competitive Strategies--France, Germany, Italy, Spain, UK

2016 Europe Cancer Diagnostics Market: Supplier Shares, Country Volume and Sales Segment Forecasts, Innovative Technologies, Competitive Strategies--France, Germany, Italy, Spain, UK

  • $ 12800
  • Industry report
  • September 2016
  • by Venture Planning Group

Complete report $19,700.  DataPack (test volumes, sales forecasts, supplier shares) $12,800. VPGMarketResearch’s new report is a study of the major business opportunities emerging in the European cance ...

Flat-Rate Access to R&D Database & Reports from La Merie Publishing

Flat-Rate Access to R&D Database & Reports from La Merie Publishing

  • $ 8470
  • Industry report
  • November 2016
  • by La Merie Publishing

Flat-Rate Access to R&D Database & Reports from La Merie Publishing - R&D Drug Pipeline Database: 1-Year Subscription - Flat-Rate Subscription to La Merie Publishing Reports & News Services A one-yea ...


ref:plp2016

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.